Mga Batayang Estadistika
| LEI | 549300NQOFKL9NON0U06 |
| CIK | 1217234 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CareDx, Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 6, 2025 |
Policy, as amended and restated effective June 13, 2025. Exhibit 10.2 CAREDX, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Most Recently Amended and Restated Effective as of June 13, 2025 CareDx, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not emplo |
|
| August 6, 2025 |
of Control and Severance Agreement, dated May 20, 2025, bet Exhibit 10.4 CAREDX, INC. CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control and Severance Agreement (this “Agreement”) is made and entered into by and between Nathan Smith (“Executive”) and CareDx, Inc., a Delaware corporation (the “Company”), effective as of May 20, 2025 (the “Effective Date”). RECITALS 1.The Board of Directors of the Company (the “Board”) believes that it is in th |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2025 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 6, 2025 |
Exhibit 99.1 CareDx Announces Second Quarter 2025 Financial Results Grew Testing Services Volume to Approximately 49,500, Increase of 13% Year-Over-Year AlloSure Kidney Testing Volumes Grew Nearly 20% Year-Over-Year Narrows Full Year 2025 Revenue Guidance to $367 Million to $373 Million BRISBANE, Calif., August 6, 2025, CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision med |
|
| August 6, 2025 |
, dated May 20, 2025, between CareDx, Inc. and Nathan Smith. Exhibit 10.5 CareDx, Inc. CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT, NON-COMPETITION, AND ARBITRATION AGREEMENT As a condition of my employment with CareDx, its subsidiaries, affiliates, successors, or assigns (together the “Company”), my receipt of confidential information, and the compensation now and hereafter paid to me and benefits provided to me by the Company, I agree to the following |
|
| August 6, 2025 |
Offer Letter, dated May 20, 2025, between CareDx, Inc. and Nathan Sm Exhibit 10.3 May 20, 2025 Dear Nathan, I am pleased to offer you a position with CareDx, Inc. (the “Company”) as Chief Financial Officer, reporting to Keith Kennedy, Chief Operating Officer. Start date will be on or before July 31, 2025 or another mutually agreed upon date. This position is a full-time, exempt, remote position based out of Salt Lake City, UT metropolitan area. Salary Effective upo |
|
| June 12, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2025 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 12, 2025 |
Amendment No. 1 to the CareDx, Inc. 2024 Equity Incentive Plan. Exhibit 10.1 AMENDMENT NO. 1 TO THE CAREDX, INC. 2024 EQUITY INCENTIVE PLAN April 23, 2025 This Amendment No 1. (this “Amendment”) to the CareDx, Inc. 2024 Equity Incentive Plan (the “Plan”) was adopted by the Board of Directors (the “Board”) of CareDx, Inc. (the “Company”), and following the Board’s approval of this Amendment as of the date first written above, will be effective as of the date on |
|
| June 3, 2025 |
Exhibit 99.1 CareDx Announces Repurchase of 5% of Outstanding Shares Board of Directors Authorizes New $50 Million Share Repurchase Program BRISBANE, Calif. - CareDx, Inc. (Nasdaq: CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2025 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 30, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2025 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 30, 2025 |
CAREDX, INC. [AMENDED AND RESTATED] CHANGE OF CONTROL AND SEVERANCE AGREEMENT This [Amended and Restated] Change of Control and Severance Agreement (this “Agreement”) is made and entered into by and between [NAME] (“Executive”) and CareDx, Inc., a Delaware corporation (the “Company”), effective as of [], 20[XX] (the “Effective Date”) [and supersedes the Change of Control and Severance Agreement, d |
|
| April 30, 2025 |
Exhibit 99.1 CareDx Reports First Quarter 2025 Results First Quarter Revenue of $84.7 Million, Increased 18% Year-Over-Year Grew Testing Services Volume to Approximately 47,100, Marking Seventh Consecutive Quarter of Sequential Testing Services Volume Growth BRISBANE, Calif., April 30, 2025, CareDx, Inc. (Nasdaq: CDNA) — today reported financial results for the first quarter ended March 31, 2025. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement |
|
| March 28, 2025 |
025, between CareDx, Inc. and Abhishek Jain. CAREDX, INC. AMENDED AND RESTATED CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change of Control and Severance Agreement (this “Agreement”) is made and entered into by and between Abhishek Jain (“Executive”) and CareDx, Inc., a Delaware corporation (the “Company”), effective as of March 27, 2025 (the “Effective Date”) and supersedes the Change of Control and Severance Agreem |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2025 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 28, 2025 |
CAREDX, INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Company Securities Effective Date: February 21, 2025 This Insider Trading Policy (this “Policy”) provides guidelines to employees, officers and directors of CareDx, Inc., and each of its subsidiaries, branches, representative offices and similar entities (collectively, the “Company”) with respect to transact |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-365 |
|
| February 28, 2025 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of CareDx, Inc. Name State or Jurisdiction of Incorporation or Organization CareDx AB Sweden CareDx Lab Solutions, Inc. Delaware CareDx Transplant Management, Inc. Nebraska CareDx Pty Ltd. Australia The Transplant Pharmacy Mississippi |
|
| February 28, 2025 |
Description of Securities of the Registrant Exhibit 4.7 Description of Securities of CareDx., Inc. The authorized capital stock of CareDx, Inc., a Delaware corporation (the “Company”), consists of: •100,000,000 shares of common stock, $0.001 par value per share (“Common Stock”); and •10,000,000 shares of preferred stock, $0.001 par value per share (“Preferred Stock”). Common Stock •Voting rights. Each holder of Common Stock is entitled to o |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2025 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 26, 2025 |
Exhibit 99.1 CareDx Announces Fourth Quarter and Full Year 2024 Financial Results Full Year 2024 Revenue Grew 19% to $334 Million Expects Full Year 2025 Revenue of $365 Million to $375 Million BRISBANE, Calif. – February 26, 2025, CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter Financial Highlights •Revenue o |
|
| January 13, 2025 |
Exhibit 99.1 CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results Fourth Quarter Revenue is Expected to Increase 30% Year-Over-Year Expects Full Year 2024 Revenue of $332 Million to $333 Million BRISBANE, Calif. — (BUSINESS WIRE)—January 13, 2025, CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter |
|
| January 13, 2025 |
The Transplant Solutions Company•J A N U A R Y 1 3 , 2 0 2 5 Patrick G, Kidney Transplant Recipient Exhibit 99.2 The Transplant Solutions Company•J A N U A R Y 1 3 , 2 0 2 5 Patrick G, Kidney Transplant Recipient Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than stateme |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 8, 2025 |
CareDx, Inc. Outside Director Compensation Policy, as amended and restated January 6, 2025. Exhibit 10.1 CAREDX, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Most Recently Amended Effective as of January 6, 2025 CareDx, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2025 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| November 14, 2024 |
CDNA / CareDx, Inc / Bellevue Asset Management (UK) Ltd. - SC 13G/A Passive Investment SC 13G/A 1 d854179dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CareDX, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 14167L103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the r |
|
| November 14, 2024 |
EX-99.A 2 d854179dex99a.htm EX-99.A EXHIBIT A JOINT FILING AGREEMENT The undersigned persons hereby agree that reports on Schedule 13G, and amendments thereto, with respect to the Common Stock of CareDX, Inc. may be filed in a single statement on behalf of each of such persons. Bellevue Asset Management (UK) Ltd. Date: November 14, 2024 By: /s/ Markus Peter Signatory Authority Name: Markus Peter T |
|
| November 8, 2024 |
CDNA / CareDx, Inc / Nikko Asset Management Americas, Inc. - SC 13G/A Passive Investment SC 13G/A 1 ef20038333sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CareDx Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 14167L103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 5, 2024 |
CDNA / CareDx, Inc / Sumitomo Mitsui Trust Holdings, Inc. - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 cdna1027248sc13ga1.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CAREDX, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 14167L103 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the ap |
|
| November 4, 2024 |
Offer Letter, dated August 30, 2024, between CareDx, Inc. and Jessica Meng. August 30, 2024 Dear Jessica, I am pleased to offer you a position with CareDx, Inc. |
|
| November 4, 2024 |
SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (this “Agreement”) is made by and between CareDx, Inc. |
|
| November 4, 2024 |
CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance Exhibit 99.1 CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance BRISBANE, Calif., November 4, 2024, CareDx, Inc. (Nasdaq: CDNA) — today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights •Total revenue of $82.9 million increased 23% year-over-year •Testing Services volume of 44,600 tests increased 16% year-over-yea |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 4, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2024 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 4, 2024 |
Consulting Agreement, dated September 30, 2024, by and between CareDx, Inc. and Alexander Johnson. CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is entered into on September 30, 2024 and is effective on September 14, 2024 (“Effective Date”) and is between CareDx, Inc. |
|
| November 4, 2024 |
CareDx, Inc. CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT, NON-COMPETITION, AND ARBITRATION AGREEMENT As a condition of my employment with CareDx, its subsidiaries, affiliates, successors, or assigns (together the “Company”), my receipt of confidential information, and the compensation now and hereafter paid to me and benefits provided to me by the Company, I agree to the following provisions of |
|
| November 4, 2024 |
CAREDX, INC. CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control and Severance Agreement (the “Agreement”) is made and entered into by and between Jessica Meng (“Executive”) and CareDx, Inc., a Delaware corporation (the “Company”), effective as of August 30, 2024 (the “Effective Date”). RECITALS 1.The Board of Directors of the Company (the “Board”) believes that it is in the best inte |
|
| October 17, 2024 |
CDNA / CareDx, Inc / STATE STREET CORP Passive Investment SC 13G/A 1 CareDxInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CAREDX INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 14167L103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| October 15, 2024 |
Exhibit 99.1 CareDx Reports Preliminary Financial Results for Third Quarter 2024 Third Quarter 2024 Financial Results to be Reported on November 4, 2024 BRISBANE, Calif., October 15, 2024 — CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solut |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2024 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 15, 2024 |
Exhibit 99.2 2024 INVESTOR DAY O C T O B E R 1 5 , 2 0 2 4 SAFE HARBOR STATEMENT These slides, and the accompanying oral presentation, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentatio |
|
| October 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 7, 2024 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2024 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 4, 2024 |
Consulting Agreement, dated September 30, 2024, between CareDx, Inc. and Alexander Johnson. CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is entered into on September 30, 2024 and is effective on September 14, 2024 (“Effective Date”) and is between CareDx, Inc. |
|
| October 4, 2024 |
SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (this “Agreement”) is made by and between CareDx, Inc. |
|
| September 13, 2024 |
Exhibit 99.3 CAREDX, INC. INDUCEMENT STOCK OPTION AGREEMENT For purposes of this Inducement Stock Option Agreement (the “Agreement”), including the Notice of Stock Option Grant (the “Notice of Grant”) and Terms and Conditions of Stock Option Grant, attached hereto as Exhibit A, certain capitalized terms will have the meanings set forth in Section 21 of the Agreement. NOTICE OF STOCK OPTION GRANT P |
|
| September 13, 2024 |
Exhibit 99.4 CAREDX, INC. INDUCEMENT STOCK OPTION AGREEMENT For purposes of this Inducement Stock Option Agreement (the “Agreement”), including the Notice of Stock Option Grant (the “Notice of Grant”) and Terms and Conditions of Stock Option Grant, attached hereto as Exhibit A, certain capitalized terms will have the meanings set forth in Section 21 of the Agreement. NOTICE OF STOCK OPTION GRANT P |
|
| September 13, 2024 |
As filed with the Securities and Exchange Commission on September 13, 2024 As filed with the Securities and Exchange Commission on September 13, 2024 Registration No. |
|
| September 13, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CareDx, Inc. (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 |
|
| September 13, 2024 |
Exhibit 99.1 CAREDX, INC. INDUCEMENT RESTRICTED STOCK UNIT AGREEMENT For purposes of this Inducement Restricted Stock Unit Agreement (the “Award Agreement”), which includes the Notice of Restricted Stock Unit Grant (the “Notice of Grant”) and the Terms and Conditions of Restricted Stock Unit Grant, attached hereto as Exhibit A, certain capitalized terms will have the meanings set forth in Section |
|
| September 13, 2024 |
Exhibit 99.2 CAREDX, INC. INDUCEMENT RESTRICTED STOCK UNIT AGREEMENT For purposes of this Inducement Restricted Stock Unit Agreement (the “Award Agreement”), which includes the Notice of Restricted Stock Unit Grant (the “Notice of Grant”) and the Terms and Conditions of Restricted Stock Unit Grant, attached hereto as Exhibit A, certain capitalized terms will have the meanings set forth in Section |
|
| September 12, 2024 |
Offer Letter, dated July 27, 2024, between CareDx, Inc. and Keith Kennedy. Exhibit 10.1 July 27, 2023 Dear Keith, I am pleased to offer you a position with CareDx, Inc. (the “Company”) as a Chief Operating Officer reporting to John Hanna, President and CEO. Start date will be September 12, 2024 or another mutually agreed upon date. This position is a full-time, exempt position, based at 8000 Marina Boulevard, Brisbane, California. Salary Effective upon commencement of yo |
|
| September 12, 2024 |
Exhibit 10.2 CAREDX, INC. CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control and Severance Agreement (the “Agreement”) is made and entered into by and between Keith S. Kennedy (“Executive”) and CareDx, Inc., a Delaware corporation (the “Company”), effective as of July 27, 2024 (the “Effective Date”). RECITALS 1. The Board of Directors of the Company (the “Board”) believes that it is |
|
| September 12, 2024 |
Exhibit 10.3 CareDx, Inc. CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT, NON-COMPETITION, AND ARBITRATION AGREEMENT As a condition of my employment with CareDx, its subsidiaries, affiliates, successors, or assigns (together the “Company”), my receipt of confidential information, and the compensation now and hereafter paid to me and benefits provided to me by the Company, I agree to the following |
|
| September 12, 2024 |
Exhibit 99.1 Final Press Release For Newswire Issue, Thursday, 9/12/24. 7:01 am ET. CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development BRISBANE, Calif.—(BUSINESS WIRE)— Septemb |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 6, 2024 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 21, 2024 |
CDNA / CareDx, Inc / GAGNON SECURITIES LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CareDx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 14167L103 (CUSIP Number) August 20, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2024 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 31, 2024 |
CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance Exhibit 99.1 CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance BRISBANE, Calif., July 31, 2024, CareDx, Inc. (Nasdaq: CDNA) — today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights •Reported total revenue of $92.3 million, an increase of 31% year-over-year. •Grew Testing Services volume to 43,700 tests, an incr |
|
| July 31, 2024 |
Patrick G, Kidney Transplant Recipient July 31, 2024 Q2 2024 Financial and Business Presentation These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| June 21, 2024 |
As filed with the Securities and Exchange Commission on June 21, 2024 As filed with the Securities and Exchange Commission on June 21, 2024 Registration No. |
|
| June 21, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CareDx, Inc. (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per s |
|
| June 18, 2024 |
CareDx, Inc. 2024 Equity Incentive Plan CareDx, Inc. 2024 Equity Incentive Plan 1.General. (a)Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to promote the creation of long-term value for the stockholders of the Company by closely aligning |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2024 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
Patrick G, Kidney Transplant Recipient Q1 2024 Earnings Presentation May 9, 2024 The Transplant Company™ Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| May 9, 2024 |
CareDx Reports First Quarter 2024 Results Raises 2024 Revenue Guidance to $274 to $282 Million Exhibit 99.1 CareDx Reports First Quarter 2024 Results Raises 2024 Revenue Guidance to $274 to $282 Million BRISBANE, Calif., May 9, 2024, CareDx, Inc. (Nasdaq: CDNA) — today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights •Reported first quarter revenue of $72.0 million. •Revenue for Testing Services of $53.8 million, an increase of 15% as comp |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement |
|
| April 25, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CareDx, Inc. (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 |
|
| April 25, 2024 |
Exhibit 99.1 CAREDX, INC. INDUCEMENT RESTRICTED STOCK UNIT AGREEMENT For purposes of this Inducement Restricted Stock Unit Agreement (the “Award Agreement”), which includes the Notice of Restricted Stock Unit Grant (the “Notice of Grant”) and the Terms and Conditions of Restricted Stock Unit Grant, attached hereto as Exhibit A, certain capitalized terms will have the meanings set forth in Section |
|
| April 25, 2024 |
Exhibit 99.2 CAREDX, INC. INDUCEMENT STOCK OPTION AGREEMENT For purposes of this Inducement Stock Option Agreement (the “Agreement”), including the Notice of Stock Option Grant (the “Notice of Grant”) and Terms and Conditions of Stock Option Grant, attached hereto as Exhibit A, certain capitalized terms will have the meanings set forth in Section 21 of the Agreement. NOTICE OF STOCK OPTION GRANT P |
|
| April 25, 2024 |
As filed with the Securities and Exchange Commission on April 25, 2024 As filed with the Securities and Exchange Commission on April 25, 2024 Registration No. |
|
| April 16, 2024 |
Change of Control and Severance Agreement, dated March 25, 2024, between CareDx, Inc. and John Hanna Exhibit 10.2 CAREDX, INC. CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control and Severance Agreement (the “Agreement”) is made and entered into by and between John Hanna (“Executive”) and CareDx, Inc., a Delaware corporation (the “Company”), effective as of March 21, 2024 (the “Effective Date”). RECITALS 1. The Board of Directors of the Company (the “Board”) believes that it is in th |
|
| April 16, 2024 |
Exhibit 10.3 CareDx, Inc. CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT, NON-COMPETITION, AND ARBITRATION AGREEMENT As a condition of my employment with CareDx, its subsidiaries, affiliates, successors, or assigns (together the “Company”), my receipt of confidential information, and the compensation now and hereafter paid to me and benefits provided to me by the Company, I agree to the following |
|
| April 16, 2024 |
Offer Letter, dated March 24, 2024, between CareDx, Inc. and John Hanna Exhibit 10.1 OFFER LETTER March 21, 2024 John Hanna 209 Chapman Drive Corte Madera, CA 94925 Dear John: I am pleased to offer you a position with CareDx, Inc. (the “Company”) as President and Chief Executive Officer, reporting directly to the Company’s Board of Directors (the “Board”). You shall have such duties, responsibilities and authorities as are commensurate with the position of President a |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2024 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 16, 2024 |
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer Exhibit 99.1 PRESS RELEASE CareDx Appoints John W. Hanna as its New President and Chief Executive Officer BRISBANE, CA, April 16, 2024 – CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. |
|
| March 11, 2024 |
CareDx Appoints Bryan Riggsbee to Its Board of Directors Exhibit 99.1 CareDx Appoints Bryan Riggsbee to Its Board of Directors BRISBANE, Calif., March 11, 2024 — CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joi |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 9, 2024 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 1, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 28, 2024 |
Exhibit 99.1 CareDx Announces Fourth Quarter and Full Year 2023 Financial Results Delivered Total Revenue of $280.3 Million, Exceeding the High End of Updated Guidance for 2023 Grew Testing Services Results for the Second Quarter in a Row BRISBANE, Calif. – February 28, 2024, CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2023. |
|
| February 28, 2024 |
Retention Bonus Letter, dated December 1, 2023, by and between CareDx, Inc. and Abhishek Jain. Exhibit 10.19 December 1, 2023 Abhishek Jain delivered via email Dear Abhishek: I am pleased to inform you that the Compensation and Human Capital Committee of the Board of Directors of CareDx, Inc. (“CareDx”) has approved a retention bonus (the “Retention Bonus”) for you in the amount of $400,000, payable in accordance with, and subject to, the terms of this letter. 25% of the Retention Bonus (ro |
|
| February 28, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2024 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 28, 2024 |
Retention Bonus Letter, dated December 1, 2023, by and between CareDx, Inc. and Alex Johnson Exhibit 10.18 December 1, 2023 Alex Johnson delivered via email Dear Alex: I am pleased to inform you that the Compensation and Human Capital Committee of the Board of Directors of CareDx, Inc. (“CareDx”) has approved a retention bonus (the “Retention Bonus”) for you in the amount of $400,000, payable in accordance with, and subject to, the terms of this letter. 25% of the Retention Bonus (rounded |
|
| February 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) CareDx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Carry Forward |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-365 |
|
| February 28, 2024 |
Exhibit 4.7 Description of Securities of CareDx., Inc. The authorized capital stock of CareDx, Inc., a Delaware corporation (the “Company”), consists of: •100,000,000 shares of common stock, $0.001 par value per share (“Common Stock”); and •10,000,000 shares of preferred stock, $0.001 par value per share (“Preferred Stock”). Common Stock •Voting rights. Each holder of Common Stock is entitled to o |
|
| February 28, 2024 |
Exhibit 97 CareDx, Inc. Clawback Policy Adopted October 11, 2023 The Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to adopt this Clawback Policy (this “Policy”), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined below). This Policy i |
|
| February 28, 2024 |
Separation Agreement, dated November 1, 2023, by and between CareDx, Inc. and Reginald Seeto, MBSS. Exhibit 10.17 SEPARATION AGREEMENT I, Reginald Seeto, have resigned from my employment with CareDx, Inc. (“Company”), effective November 1, 2023 (“Resignation Date”). The “Effective Date” of this Separation Agreement is the date of execution. 1.Consideration: In exchange for this Agreement, I shall be entitled to receive the payments and benefits set forth in this Section 1 (collectively, the “Con |
|
| February 28, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of CareDx, Inc. Name State or Jurisdiction of Incorporation or Organization CareDx AB Sweden CareDx Lab Solutions, Inc. Delaware CareDx Transplant Management, Inc. Nebraska CareDx Pty Ltd. Australia The Transplant Pharmacy Mississippi HLA Data Systems, LLC Texas MediGO, Inc. Nebraska |
|
| February 28, 2024 |
Consulting Agreement, dated October 30, 2023, by and between CareDx, Inc. and Reginald Seeto, MBBS. Exhibit 10.16 LEGAL CONSULTING AGREEMENT This Legal Consulting Agreement (“Agreement”) is entered into on October 30, 2023 and is effective on November 2, 2023 (“Effective Date”) and is between CareDx, Inc., with a business address at 8000 Marina Blvd, Brisbane, CA 94005 (“CareDx” or the “Company”) and Reginald Seeto (“Consultant”), following Consultant’s resignation of employment pursuant to the |
|
| February 14, 2024 |
CDNA / CareDx, Inc / ArrowMark Colorado Holdings LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
CDNA / CareDx, Inc / GAGNON SECURITIES LLC - SC 13G/A Passive Investment SC 13G/A 1 caredx13ga1.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CareDx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 14167L103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| February 13, 2024 |
CDNA / CareDx, Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0531-caredxinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: CareDx Inc Title of Class of Securities: Common Stock CUSIP Number: 14167L103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursu |
|
| February 13, 2024 |
CDNA / CareDx, Inc / Bellevue Asset Management (UK) Ltd. - SC 13G/A Passive Investment SC 13G/A 1 d749646dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CareDX, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 14167L103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the ru |
|
| February 12, 2024 |
CDNA / CareDx, Inc / Nikko Asset Management Americas, Inc. - SC 13G Passive Investment SC 13G 1 ef20021444sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* CareDx Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 14167L103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 5, 2024 |
CDNA / CareDx, Inc / Sumitomo Mitsui Trust Holdings, Inc. Passive Investment SC 13G 1 cdna130245sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* CAREDX, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 14167L103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to des |
|
| January 29, 2024 |
CDNA / CareDx, Inc / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm244117d13sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* CareDX, Inc. (Name of Issuer) Common stock (Title of Class of Securities) 14167L103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| January 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) CareDx, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, par v |
|
| January 12, 2024 |
As filed with the Securities and Exchange Commission on January 12, 2024 As filed with the Securities and Exchange Commission on January 12, 2024 Registration No. |
|
| January 9, 2024 |
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023 Exhibit 99.1 CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023 BRISBANE, Calif. — (BUSINESS WIRE)—January 9, 2024, CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –today reported preliminary financial |
|
| January 9, 2024 |
EX-99.2 Exhibit 99.2 ™ The Transplant Company Focused on improving care across the entire transplant patient journey Corporate Presentation January 9, 2024 Patrick G. Kidney Transplant Recipient Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, includi |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2024 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| December 22, 2023 |
Outside Director Compensation Policy, last amended December 21, 2023. Exhibit 10.1 CAREDX, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Most Recently Amended Effective as of December 21, 2023 CareDx, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of t |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 21, 2023 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 8, 2023 |
CareDx Reports Third Quarter 2023 Results Exhibit 99.1 CareDx Reports Third Quarter 2023 Results BRISBANE, Calif., November 8, 2023 - CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers - today reported financial results for the third quarter ended September 30, 2023. Third Qua |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2023 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 8, 2023 |
Legal Consulting Agreement, dated September 20, 2023, by and between CareDx, Inc. and Abraham Ronai. Exhibit 10.2 LEGAL CONSULTING AGREEMENT This Legal Consulting Agreement (“Agreement”) is entered into on September 20, 2023 and is effective on October 1, 2023 (“Effective Date”) and is between CareDx, Inc., with a business address at 8000 Marina Blvd, Brisbane, CA 94005 (“CareDx” or the “Company”) and Abraham Ronai (“Consultant”), following Consultant’s resignation of employment pursuant to the f |
|
| November 8, 2023 |
Separation Agreement, dated September 20, 2023, by and between CareDx, Inc. and Abraham Ronai. Exhibit 10.1 SEPARATION AGREEMENT I, Abraham Ronai, have resigned from my employment with CareDx, Inc. (“Company”), effective September 30, 2023 (“Resignation Date”). The “Effective Date” of this Separation Agreement will be the eighth day following the date that I sign and return this Agreement to the Company, provided I do not rescind this Agreement in the seven days following the date that I si |
|
| November 1, 2023 |
Exhibit 99.1 CareDx Announces CEO Transition Board Establishes Office of the CEO, Conducts Search for Successor Raises 2023 Revenue Guidance BRISBANE, Calif., November 1, 2023 (BUSINESS WIRE ) — CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2023 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2023 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2023 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2023 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 8, 2023 |
CareDx Reports Second Quarter 2023 Results Exhibit 99.1 CareDx Reports Second Quarter 2023 Results BRISBANE, Calif., August 8, 2023 - CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers - today reported financial results for the second quarter ended June 30, 2023. Second Quarter |
|
| June 20, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CAREDX, INC. CareDx, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: A.The name of the Corporation is CareDx, Inc. The Corporation was originally incorporated under the name “Hippocratic Engineering, Inc.”, and the date of filing o |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2023 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 10, 2023 |
Exhibit 10.2 ***Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit. *** AGREEMENT REGARDING PAYMENT OF ROYALTIES AND AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE Effective the 3rd |
|
| May 10, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) CareDx, Inc. |
|
| May 10, 2023 |
EX-4.15 Exhibit 4.15 CareDx, Inc. INDENTURE Dated as of [ ] [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 4 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establishme |
|
| May 10, 2023 |
Power of Attorney (included on the signature page to this Registration Statement). Table of Contents As filed with the Securities and Exchange Commission on May 10, 2023 Registration No. |
|
| May 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2023 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 10, 2023 |
CareDx, Inc. Outside Director Compensation Policy, effective April 1, 2023. Exhibit 10.1 CareDx, Inc. OUTSIDE DIRECTOR COMPENSATION POLICY Most Recently Amended Effective as of April 1, 2023 CareDx, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the C |
|
| May 10, 2023 |
CareDx Reports First Quarter 2023 Results Exhibit 99.1 CareDx Reports First Quarter 2023 Results BRISBANE, Calif., May 10, 2023 - CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers - today reported financial results for the first quarter ended March 31, 2023. First Quarter 202 |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 14, 2023 |
PRELIMINARY COPY DATED APRIL 14, 2023 – SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 29, 2023 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 28, 2023 |
Amended and Restated Bylaws, effective as of March 24, 2023 EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CAREDX, INC. As Amended and Restated on March 24, 2023 TABLE OF CONTENTS Page Article I — CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 Article II — MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOCKHOLDERS’ MEETINGS 7 2.6 QUORUM 7 2.7 A |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 24, 2023 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 13, 2023 |
CDNA / Caredx Inc / GAGNON SECURITIES LLC - SC 13G Passive Investment SC 13G 1 caredx13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CareDx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 14167L103 (CUSIP Number) March 6, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2023 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 27, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2023 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 27, 2023 |
CareDx Reports Fourth Quarter and Full Year 2022 Results Exhibit 99.1 CareDx Reports Fourth Quarter and Full Year 2022 Results BRISBANE, Calif., February 27, 2023 - CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the fourth quarter and full year ende |
|
| February 27, 2023 |
cdnaq4andfy2022earningsp Leslie M, Kidney Transplant Recipient Focused on improving care across the entire transplant patient journey The Transplant Company™ Earnings Presentation Q4 and FY 2022 These slides and the accompanying oral presentation contain forward-looking statements, including statements with respect to expectations regarding CareDx’s upcoming milestones, vision and 2023 revenue guidance. |
|
| February 27, 2023 |
Power of Attorney is contained on the signature page. S-8 As filed with the Securities and Exchange Commission on February 27, 2023 Registration No. |
|
| February 27, 2023 |
Description of Securities of CareDx, Inc. Exhibit 4.8 Description of Securities of CareDx., Inc. The authorized capital stock of CareDx, Inc., a Delaware corporation (the “Company”), consists of: •100,000,000 shares of common stock, $0.001 par value per share (“Common Stock”); and •10,000,000 shares of preferred stock, $0.001 par value per share (“Preferred Stock”). Common Stock •Voting rights. Each holder of Common Stock is entitled to o |
|
| February 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-365 |
|
| February 27, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) CareDx, Inc. |
|
| February 27, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of CareDx, Inc. Name State or Jurisdiction of Incorporation or Organization CareDx AB Sweden CareDx Lab Solutions, Inc. Delaware CareDx Transplant Management, Inc. Nebraska CareDx Pty Ltd. Australia The Transplant Pharmacy Mississippi |
|
| February 15, 2023 |
CDNA / CareDx Inc / ArrowMark Colorado Holdings LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
CDNA / CareDx Inc / Bellevue Asset Management (UK) Ltd. - SC 13G Passive Investment SC 13G 1 d441311dsc13g.htm SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CAREDX, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 14167L103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 14, 2023 |
EX-99.A 2 d441311dex99a.htm EX-99.A Exhibit A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned. Bellevue Group AG Date: February 14, 2023 By: /s/ Michael Hutter Signatory Authority Name: Michael Hutter Title: Chief Financial Officer Date: February 14, 2023 By: /s/ |
|
| February 10, 2023 |
CDNA / CareDx Inc / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm235555d13sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* CareDX, Inc. (Name of Issuer) Common stock (Title of Class of Securities) 14167L103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 9, 2023 |
CDNA / CareDx Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: CareDx Inc. Title of Class of Securities: Common Stock CUSIP Number: 14167L103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| February 8, 2023 |
CDNA / CareDx Inc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* CareDx Inc (Name of Issuer) Common Stock (Title of Class of Securities) 14167L103 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| January 10, 2023 |
CDNA / CareDx Inc / ALGER ASSOCIATES INC - CAREDX, INC. Passive Investment SC 13G/A 1 d440941dsc13ga.htm CAREDX, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* CareDx, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 14167L103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 9, 2023 |
Focused on improving care across the entire transplant patient journey The Transplant Company™ Corporate Presentation: January 2023 Exhibit 99. |
|
| January 9, 2023 |
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022 EX-99.1 2 d443407dex991.htm EX-99.1 Exhibit 99.1 CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022 BRISBANE, Calif., January 9, 2023— CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported pr |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2023 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| December 6, 2022 |
CareDx Announces $50 Million Stock Repurchase Program EX-99.1 Exhibit 99.1 December 6, 2022 CareDx Announces $50 Million Stock Repurchase Program BRISBANE, Calif.—(BUSINESS WIRE) – CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its Board of Directors has authori |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 3, 2022 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 21, 2022 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 3, 2022 |
CareDx Reports Third Quarter 2022 Results Exhibit 99.1 CareDx Reports Third Quarter 2022 Results BRISBANE, Calif., November 3, 2022 - CareDx, Inc. (Nasdaq: CDNA) ? The Transplant Company? focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers - today reported financial results for the third quarter ended September 30, 2022. Recent Hi |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2022 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 3, 2022 |
Leslie M, Kidney Transplant Recipient Focused on improving care across the entire transplant patient journey The Transplant Company? Earnings Presentation Q3 2022 These slides and the accompanying oral presentation contain forward-looking statements, including statements with respect to expectations regarding CareDx?s upcoming milestones, vision and 2022 revenue guidance. |
|
| November 3, 2022 |
Exhibit 10.2 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this ?Amendment?) is entered into as of this 27th day of June, 2022 (the ?Third Amendment Execution Date?), by and between BMR-BAYSHORE BOULEVARD LP, a Delaware limited partnership (?Landlord?), and CAREDX, INC., a Delaware corporation (?Tenant?). RECITALS A.WHEREAS, Landlord, formerly known as BMR-Bayshore Boulevard LLC, a Delaw |
|
| November 3, 2022 |
Lease, dated February 28, 2022, by and between the Registrant and One Miracle Place, LLC. Exhibit 10.1 OFFICE LEASE AGREEMENT (11808 Miracle Hills) THIS OFFICE LEASE AGREEMENT (?Lease?) is made as of February 28, 2022, between One Miracle Place, LLC, a Nebraska limited liability company (?Landlord?), and CareDX Inc., a Delaware corporation (?Tenant?). ARTICLE 1 ? DEFINITIONS Whenever used in this Lease, the following terms shall have the meanings indicated below: Additional Rent: As de |
|
| October 11, 2022 |
CDNA / CareDx Inc / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| September 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 7, 2022 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 30, 2022 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 4, 2022 |
Promotion Letter, dated May 21, 2022, by and between the Registrant and Abhishek Jain. Exhibit 10.3 May 21, 2022 Private & Confidential Abhishek Jain Dear Abhishek, It is my pleasure to confirm your appointment as Interim Chief Financial Officer reporting to Reg Seeto, President & CEO. This is a full-time exempt role at the Company with an annual salary of $305,000.00 paid on a semi-monthly basis on our regular paydays. Deductions required by law or authorized by you will be taken f |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2022 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 4, 2022 |
Consulting Agreement, dated May 20, 2022, by and between the Registrant and Ankur Dhingra. Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (?Agreement?) is entered into on May 20, 2022 and is effective May 27, 2022 (?Effective Date?) and is between CareDx, Inc., with a business address at 1 Tower Place, 9th Floor, South San Francisco, CA 94080, (?CareDx?) and Ankur Dhingra, with a business address at 1382 Buckthorne Way, San Jose, CA 95129 (?Consultant?). CareDx and Consulta |
|
| August 4, 2022 |
Exhibit 10.1 *** Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) of the type that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (?[***]?) in this exhibit. *** S09-367: GWK AMENDED AND RESTATED EXCLUSIVE AGREEMENT This Amended and Restated Agreement (?Restated Agreement?) between THE |
|
| August 4, 2022 |
CareDx Reports Second Quarter 2022 Results Exhibit 99.1 CareDx Reports Second Quarter 2022 Results BRISBANE, Calif., August 4, 2022 - CareDx, Inc. (Nasdaq: CDNA) ? The Transplant Company? focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers - today reported financial results for the second quarter ended June 30, 2022. Recent Highlig |
|
| August 4, 2022 |
Lease, dated June 14, 2022, by and between the Registrant and HCP Life Science REIT, Inc. Exhibit 10.4 THE TOWERS AT SIERRA POINT LEASE This Lease (the ?Lease?), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the ?Summary?), below, is made by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation (?Landlord?), and CAREDX, INC., a Delaware corporation (?Tenant?). SUMMARY OF BASIC LEASE INFORMATION TERMS OF LEASE DESCRIPTION Date: June 14, |
|
| June 17, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2022 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2022 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 5, 2022 |
CareDx Reports First Quarter 2022 Results Exhibit 99.1 CareDx Reports First Quarter 2022 Results SOUTH SAN FRANCISCO, Calif., May 5, 2022 - CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers - today reported financial results for the first quarter ended March 31, 2022. Recent |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2022 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| May 2, 2022 |
DEF 14A 1 caredxdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| May 2, 2022 |
DEFA14A 1 caredxinc-defa14a2.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| April 15, 2022 |
Sales Agreement, dated April 14, 2022, by and between the Registrant and Jefferies LLC. EX-1.1 2 d341412dex11.htm EX-1.1 Exhibit 1.1 CAREDX, INC. Shares of Common Stock (par value $0.001 per share) Sales Agreement April 14, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: CareDx, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Jefferies LLC (the “Agent”), as follows: 1. Issuance and Sale of Shares. The C |
|
| April 15, 2022 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-239049 PROSPECTUS SUPPLEMENT (To Prospectus dated June 9, 2020) $200,000,000 Common Stock We have entered into a Sales Agreement with Jefferies LLC, or Jefferies, dated April 14, 2022, relating to shares of our common stock offered by this prospectus supplement. In accordance with the terms of the sales agreement, under this p |
|
| April 15, 2022 |
Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) CareDx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(2) Fees to Be Paid Equity |
|
| April 15, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2022 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 13, 2022 |
As filed with the Securities and Exchange Commission on April 13, 2022 As filed with the Securities and Exchange Commission on April 13, 2022 Registration No. |
|
| April 13, 2022 |
EX-FILING FEES 4 d345679dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) CareDx, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Re |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2022 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 24, 2022 |
Description of Securities of CareDx, Inc. Exhibit 4.8 Description of Securities of CareDx., Inc. The authorized capital stock of CareDx, Inc., a Delaware corporation (the ?Company?), consists of: ?100,000,000 shares of common stock, $0.001 par value per share (?Common Stock?); and ?10,000,000 shares of preferred stock, $0.001 par value per share (?Preferred Stock?). Common Stock ?Voting rights. Each holder of Common Stock is entitled to o |
|
| February 24, 2022 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of CareDx, Inc. Name State or Jurisdiction of Incorporation or Organization CareDx International AB Sweden CareDx AB Sweden CareDx Lab Solutions, Inc. Delaware CareDx Transplant Management, Inc. Nebraska CareDx GmbH Austria CareDx Pty Ltd. Australia MedActionPlan.com LLC New Jersey The Transplant Pharmacy Mississippi |
|
| February 24, 2022 |
CareDx Reports Fourth Quarter and Full Year 2021 Results Exhibit 99.1 CareDx Reports Fourth Quarter and Full Year 2021 Results SOUTH SAN FRANCISCO, Calif., February 24, 2022 - CareDx, Inc. (Nasdaq: CDNA) ? The Transplant Company? focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers - today reported financial results for the fourth quarter and ful |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-365 |
|
| February 14, 2022 |
CDNA / CareDx Inc / ALGER ASSOCIATES INC - CAREDX, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* CareDx, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 14167L103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 9, 2022 |
CDNA / CareDx Inc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* CareDx Inc (Name of Issuer) Common Stock (Title of Class of Securities) 14167L103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 9, 2022 |
CDNA / CareDx Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: CareDx Inc. Title of Class of Securities: Common Stock CUSIP Number: 14167L103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| February 9, 2022 |
CDNA / CareDx Inc / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm225659d23sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* CareDX, Inc. (Name of Issuer) Common stock (Title of Class of Securities) 14167L103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2022 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 10, 2022 |
Exhibit 99.1 CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021 Another Record Revenue Quarter Caps Off Strong Year SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 - CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company? focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and care |
|
| January 5, 2022 |
Exhibit 99.1 CareDx Expands Its Medication Adherence Services with the Acquisition of The Transplant Pharmacy CareDx will Directly Support Organ Transplant Patients with Specialty Prescription Services SOUTH SAN FRANCISCO, Calif., January 5, 2022 - CareDx, Inc. (Nasdaq: CDNA) ? The Transplant Company?, focused on the discovery, development, and commercialization of clinically differentiated, high- |
|
| January 5, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2022 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| November 10, 2021 |
Exhibit 99.1 CareDx Acquires MedActionPlan to Directly Support Patients with Better Adherence MedActionPlan adds a robust medication adherence platform to the CareDx digital suite, currently used in more than 100 hospitals and health systems SOUTH SAN FRANCISCO, Calif., November 10, 2021 - CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and |
|
| November 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2021 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2021 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 1, 2021 |
CareDx Completes Orderly Management Transition Exhibit 99.1 CareDx Completes Orderly Management Transition SOUTH SAN FRANCISCO, Calif., November 1, 2021 ? CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that the company has completed its transition f |
|
| October 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 28, 2021 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 28, 2021 |
CareDx Reports Third Quarter 2021 Results Increases Full Year Revenue Guidance Exhibit 99.1 CareDx Reports Third Quarter 2021 Results Increases Full Year Revenue Guidance SOUTH SAN FRANCISCO, Calif., October 28, 2021 (GLOBE NEWSWIRE) - CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 15, 2021 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 15, 2021 |
Exhibit 99.1 CareDx Names Longtime Patient Advocate Art Torres to Board of Directors Torres Adds Expertise in Regenerative Medicine and Organ Procurement to the CareDx Board SOUTH SAN FRANCISCO, Calif., SEPT 15, 2021 (GLOBE NEWSWIRE) ? CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-va |
|
| August 6, 2021 |
As filed with the Securities and Exchange Commission on August 6, 2021 As filed with the Securities and Exchange Commission on August 6, 2021 Registration No. |
|
| July 29, 2021 |
2014 Equity Incentive Plan, as amended. Exhibit 4.2 CAREDX, INC. 2014 EQUITY INCENTIVE PLAN, AS AMENDED 1.Purposes of the Plan. The purposes of this Plan are: ?to attract and retain the best available personnel for positions of substantial responsibility, ?to provide additional incentive to Employees, Directors and Consultants, and ?to promote the success of the Company?s business. The Plan permits the grant of Incentive Stock Options, |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2021 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 29, 2021 |
Exhibit 99.1 CareDx Reports 77% Revenue Growth for Second Quarter of 2021 and Increases Full Year Revenue Guidance SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) - CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregi |
|
| July 29, 2021 |
CareDx, Inc. 2019 Inducement Equity Incentive Plan. EX-4.7 4 exhibit47.htm EX-4.7 Exhibit 4.7 CAREDX, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the |
|
| July 29, 2021 |
2016 Inducement Equity Incentive Plan. Exhibit 4.5 CAREDX, INC. 2016 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nonstatutory Stock O |
|
| July 20, 2021 |
Promotion Letter, dated July 12, 2021, between CareDx, Inc. and Alex Johnson. Exhibit 10.1 July 12, 2021 Alex Johnson Dear Alex, It is my pleasure to officially offer you a promotion to Chief Business Officer & Head of Testing Services reporting to Reg Seeto, President & CEO. This is a full-time exempt role at the Company with annual salary of $375,000.00 paid on a semi-monthly basis on our regular paydays. Deductions required by law or authorized by you will be taken from |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 19, 2021 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 12, 2021 |
CDNA / CareDx Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: CareDx Inc. Title of Class of Securities: Common Stock CUSIP Number: 14167L103 Date of Event Which Requires Filing of this Statement: June 30, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-1( |
|
| July 1, 2021 |
Exhibit 99.1 CareDx Appoints Dr. Hannah Valantine to its Board of Directors Dr. Valantine brings deep transplant and diversity leadership expertise to the CareDx board SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) ? CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value he |
|
| July 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2021 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 18, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CAREDX, INC. Adopted June 15, 2021 TABLE OF CONTENTS Page ARTICLE I ? CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II ? MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 1 2.5 NOTICE OF STOCKHOLDERS? MEETINGS 5 2.6 QUORUM 5 2.7 ADJOURNED MEETING; NOTICE 5 |
|
| June 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2021 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 18, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CAREDX, INC. CareDx, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), certifies that: A. The name of the Corporation is CareDx, Inc. The Corporation was originally incorporated under the name ?Hippocratic Engineering, Inc.,? and the date of filing |
|
| June 3, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2021 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 3, 2021 |
Exhibit 99.1 CareDx Advances Artificial Intelligence in Transplantation Partnership with OrganX to develop decision support systems SOUTH SAN FRANCISCO, Calif., June 3, 2021 (GLOBE NEWSWIRE) - CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant pat |
|
| May 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2021 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| May 5, 2021 |
CareDx Reports First Quarter 2021 Results Strong start to 2021, raising full year guidance Exhibit 99.1 CareDx Reports First Quarter 2021 Results Strong start to 2021, raising full year guidance SOUTH SAN FRANCISCO, Calif., May 5, 2021 (GLOBE NEWSWIRE) - CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today r |
|
| April 30, 2021 |
DEF 14A 1 caredxinc-def141.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 11, 2021 |
Offer Letter, dated February 11, 2021, between CareDx, Inc. and Ankur Dhingra. Exhibit 10.1 OFFER LETTER February 11, 2021 Ankur Dhingra [?***?] [?***?] Dear Ankur, I am pleased to offer you a position with CareDx, Inc. (the ?Company?) as Chief Financial Officer reporting to Reg Seeto, President and Chief Executive Officer. Start date will be March 25, 2021 or another mutually agreed upon date. This position is a full-time, exempt position, based out of our headquarters in S |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 11, 2021 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 11, 2021 |
CareDx Names Ankur Dhingra as New Chief Financial Officer EX-99.1 Exhibit 99.1 CareDx Names Ankur Dhingra as New Chief Financial Officer SOUTH SAN FRANCISCO, Calif., March 11, 2021 — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the appointment of Ankur Dhingra as |
|
| February 24, 2021 |
Description of Securities of CareDx, Inc. Exhibit 4.8 Description of Securities of CareDx., Inc. The authorized capital stock of CareDx, Inc., a Delaware corporation (the ?Company?), consists of: ?100,000,000 shares of common stock, $0.001 par value per share (?Common Stock?); and ?10,000,000 shares of preferred stock, $0.001 par value per share (?Preferred Stock?). Common Stock ?Voting rights. Each holder of Common Stock is entitled to o |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2021 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 24, 2021 |
CareDx Reports Fourth Quarter and Full Year 2020 Results Exhibit 99.1 CareDx Reports Fourth Quarter and Full Year 2020 Results SOUTH SAN FRANCISO, Calif., February 24, 2021 (GLOBE NEWSWIRE) - CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for |
|
| February 24, 2021 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of CareDx, Inc. Name State or Jurisdiction of Incorporation or Organization CareDx International AB Sweden CareDx AB Sweden CareDx Lab Solutions, Inc. Delaware CareDx Transplant Management, Inc. Nebraska CareDx GmbH Austria CareDx Pty Ltd. Australia |
|
| February 24, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-365 |
